
Lupin adds chief corporate development officer
pharmafile | April 25, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Lupin, theresa stevens
Mumbai-based pharma firm Lupin has hired Theresa Stevens to be its chief corporate development officer.
Stevens will be assuming responsibility for the firm’s M&A and speciality business strategy, and prior to joining Lupin she was conducting the same role at Aptalis Pharma.
Before Aptalis, Stevens was with Novartis for over nine years and held various positions of increasing responsibility.
She started her career as a research scientist at Dupont and has practiced corporate law at Pennie & Edmonds (Jones Day). Having worked with Aptalis and Novartis, Stevens has over 27 years of experience in the pharma and biotech sector comprising managing strategy, corporate development, M&A and licensing.
Vinita Gupta, chief executive at Lupin says: “I am very pleased to welcome Theresa to the Lupin family. I am sure her rich experience in the areas of M&A and Speciality Strategy within the Pharmaceutical and Biotech industry sector will help Lupin’s growth plans.”
Related Content

Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership …

Lupin scoops up women’s health specialist Symbiomix for $150 million
The US arm of Mumbai’s Lupin Pharmaceuticals has announced that it is has acquired US-based …
Lupin drops on FDA observations; company reassures of no disruption at facility
Shares of India’s Lupin dropped over 14% Tuesday following news the US Food and Drug …






